Meeting Overview | We are pleased to invite you to our educational poster session titled “Myeloma Therapy: Strategies in Evolution,” to be held on 4 May 2011 at the 13th International Myeloma Workshop in Paris, France.
During this interactive poster session reception, leaders in the field will discuss recent advances in the field of myeloma.
|
Date and Location | 4 May 2011
20.30 – 22.00
Salle Soufflot
Carrousel du Louvre
Paris, France |
Target Audience | This educational activity is designed for hematologists, oncologists and other healthcare providers actively involved and interested in the management of myeloma. |
Learning Objectives | Upon completion of this educational activity, participants should be able to:
- Explain the mechanism of action of current and emerging therapies for multiple myeloma
- Evaluate changing outcomes in multiple myeloma based on the emerging use of novel bone-targeted therapies
- Summarize data surrounding novel agents in the management of relapsed/refractory multiple myeloma and integrate new findings into clinical practice
|
Faculty | Co-Chairs:
Jesus F. San-Miguel, MD, PhD
Hospital Universitario de Salamanca
Salamanca, Spain
|
Mario Boccadoro, MD
University of Torino
Torino, Italy
|
Faculty:
Sagar Lonial, MD
Emory University
Atlanta, Georgia, United States
|
Gareth J. Morgan, MD, PhD
The Institute of Cancer Research
London, United Kingdom
|
Poster Discussants:
Melissa Alsina, MD
Marina Bolzoni
Benjamin Djulbegovic, MD, PhD
Martin Kropff, MD
Massimo Offidani, MD
Paul G. Richardson, MD
|
|
 Agenda |
| Light dinner will be served |
|
20.30 |
|
Welcome Reception and Poster Viewing
- COMPARE—Results of a Randomized Study to Assess the Renal Safety and Efficacy of Ibandronate and Zoledronate in Multiple Myeloma Patients
Poster discussant: Martin Kropff, MD
- Optimizing Bone Disease in Myeloma: Zoledronic Acid Plus Thalidomide Combinations Improves Survival and Bone Endpoints: Results of the MRC Myeloma IX Trial
Poster discussant: Gareth J. Morgan, MD, PhD
- The Immunomodulatory Drugs Lenalidomide and Pomalidomide Inhibit Multiple Myeloma-Induced Osteoclast Formation and RANKL/OPG Ratio in Myeloma Microenvironment Targeting the Expression of Adhesion Molecules
Poster discussant: Marina Bolzoni
- Comparative Effectiveness of Bisphosphonates in Multiple Myeloma
Poster discussant: Benjamin Djulbegovic, MD, PhD
- PANORAMA 2: A Phase II Study of Panobinostat (LBH589) in Combination with Bortezomib (BTZ) and Dexamethasone (DEX) in Patients with Relapsed and BTZ-Refractory Multiple Myeloma (MM)
Poster discussant: Melissa Alsina, MD
- Phase Ib Study of Oral Panobinostat (LBH589) plus Intravenous Bortezomib in Patients (Pts) with Relapsed (Rel) or Rel and Refractory (Ref) Multiple Myeloma
Poster discussant: Jesus F. San-Miguel, MD, PhD
- Elotuzumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma: Interim Results of Phase 2 Study
Poster discussant: Paul G. Richardson, MD
- Melphalan, Thalidomide and Prednisone (MPT) Combined with Oral Panobinostat in Patients with Relapsed/Refractory MM: A Phase I-II Study
Poster discussant: Massimo Offidani, MD
- Phase I Study of Vorinostat, Lenalidomide, and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Excellent Tolerability and Promising Activity in a Heavily Pretreated Population
Poster discussant: Paul G. Richardson, MD
- Results of PX-171-003-A1, An Open-Label, Single-Arm, Phase 2 (Ph 2) Study of Carfilzomib (CFZ) in Patients (pts) with Relapsed and Refractory Multiple Myeloma (MM)
Poster discussant: Sagar Lonial, MD
|
|
21.00 |
|
Clinical Insights in Bone-Targeted Therapy for Multiple
Myeloma
Gareth J. Morgan, MD, PhD
|
|
21.30 |
|
Emerging Options for Relapsed/Refractory Multiple Myeloma
Sagar Lonial, MD
|
| 22.00 |
|
Concluding Remarks
|
|

|
|
|
Organizer | This meeting is a prIME Oncology activity.
|
Support | Support for this activity has been provided by Novartis Oncology.
|
Fee Information | There is no fee to attend this educational activity. Light dinner will be served. Preregistration is not required for this event, however space is limited. |
|